Single-agent Idelalisib for Previously Treated Low-grade Lymphoma: A Phase 1/2 Study of Safety, Efficacy, and Flow-cytometric Assessment of Tumor-cell Signaling Events
Phase of Trial: Phase I/II
Latest Information Update: 23 Dec 2016
At a glance
- Drugs Idelalisib (Primary)
- Indications B cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Gilead Sciences
- 10 Jun 2017 Biomarkers information updated
- 15 Oct 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 30 Jun 2015 Planned End Date changed from 1 Mar 2016 to 1 Oct 2016 as reported by ClinicalTrials.gov record.